Marksans Pharma Limited has submitted to the Exchange, the unaudited financial results for the quarter and half year ended September 30, 2025.

Results View source PDF Explain this filing

MARKSANS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.8%Reaction day

₹187.33

prior close

₹191.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%+2.9% vs market

Pharmaceuticals peers, median of 157sector+0.0%+2.8% vs sector

On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 2.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.3

10m

+0.5

15m

+0.5

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.8-0.1+2.9+0.0+2.8

Next day

+4.2+0.5+3.6-0.1+4.3

+2.5-0.3+2.8-0.9+3.5

+0.7-0.5+1.2-1.4+2.1

+3.2-0.8+4.0-1.6+4.7

+2.4-2.3+4.7-2.3+4.7

+1.2-2.8+4.0-3.1+4.3

15d

-1.9-4.9+3.0-3.6+1.7

+1.5-4.7+6.2-4.4+5.8

-7.9-7.7-0.1-5.6-2.2

-4.5-7.8+3.3-10.7+6.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Marksans Pharma has filed its unaudited financial results for the quarter and half year ended September 30, 2025 with the stock exchange. The filing covers both the standalone Q2 (July–September 2025) and the first half of FY26 performance. Detailed line items such as revenue, operating profit, and net profit are not visible from the headline alone. Investors will need to look at the full results document for specific numbers and segment performance. This is a routine regulatory filing required of all listed companies within 45 days of quarter-end.

Likely market impact

Neutral to mildly informative — the filing itself is procedural, but the underlying numbers (once reviewed) could move the stock depending on whether revenue, margins, and profits beat or miss street expectations.